VANASHYA FAWWAZSKA ATHAWEYA, - (2024) ANALISIS EFEKTIVITAS BIAYA DEFERIPRON DAN DEFERASIROKS PADA PASIEN TALASEMIA MAYOR ANAK DI SALAH SATU RUMAH SAKIT KOTA BANDUNG. Skripsi thesis, Sekolah Tinggi Farmasi Indonesia.
![[img]](http://repository.stfi.ac.id/style/images/fileicons/text.png) |
Text
S_PSSF_A201096_Title.pdf Download (584kB) |
|
Text
S_PSSF_A201096_Chapter1.pdf Restricted to Repository staff only Download (190kB) |
|
Text
S_PSSF_A201096_Chapter2.pdf Restricted to Repository staff only Download (276kB) |
|
Text
S_PSSF_A201096_Chapter3.pdf Restricted to Repository staff only Download (216kB) |
|
Text
S_PSSF_A201096_Chapter4.pdf Restricted to Repository staff only Download (317kB) |
|
Text
S_PSSF_A201096_Chapter5.pdf Restricted to Repository staff only Download (147kB) |
|
Text
S_PSSF_A201096_Appendix.pdf Restricted to Repository staff only Download (818kB) |
Abstract
Talasemia adalah sekelompok penyakit kelainan darah yang diwariskan secara genetik. Penyandang talasemia mengalami gangguan dalam produksi hemoglobin, yang dapat menyebabkan anemia yang parah dan berbagai komplikasi terkait sehingga transfusi darah diperlukan dalam meningkatkan kualitas hidup pasien talasemia mayor, namun karena dapat menyebabkan kelebihan zat besi, maka diperlukan terapi kelasi besi. Obat kelasi besi sangat diperlukan oleh semua pasien yang mendapatkan transfusi PRC berulang, untuk mengeluarkan kelebihan besi yang disebabkan akibat anemia kronis dan tata laksana utama (transfusi PRC) yang diberikan, Deferiprone dan deferasiroks merupakan obat kelasi besi yang paling sering digunakan di Indonesia. Penelitian ini dilakukan untuk membandingkan biaya dan efektivitas biaya deferipron dan deferasiroks pada penderita talasemia mayor anak di RSUP Dr. Hasan Sadikin Bandung. Penelitian ini menggunakan metode cross sectional dan data diambil secara retrospektif. Hasil penelitian ini menunjukan bahwa efektivitas deferasiroks lebih besar dibandingkan deferiprone, namun biayanya jauh lebih tinggi. Hasil nilai ACER menunjukan bahwa deferasiroks merupakan obat yang cost-effectiveness antara deferiprone dan deferasiroks pada penderita talasemia mayor anak di RSUP Dr. Hasan Sadikin Bandung. ---- Thalassemia is a group of genetically inherited blood disorders. Patients with thalassemia have impaired hemoglobin production, which can lead to severe anemia and related complications, so blood transfusions are necessary to improve the quality of life of thalassemia major patients, but because they can cause iron overload, iron chelation therapy is required. Iron chelation drugs are needed by all patients who get repeated PRC transfusions, to remove excess iron caused by chronic anemia and the main management (PRC transfusion) given, Deferiprone and deferasirox are the most commonly used iron chelation drugs in Indonesia. This study was conducted to compare the cost and cost effectiveness of deferiprone and deferasirox in children with thalassemia major at Dr. Hasan Sadikin Hospital Bandung. This study used cross sectional method and the data was taken retrospectively. The results of this study showed that the effectiveness of deferasirox was greater than deferiprone, but the cost was much higher. The ACER value showed that deferasirox was the most costeffective drug between deferiprone and deferasirox in children with thalassemia major in Dr. Hasan Sadikin Hospital Bandung
| Item Type: | Thesis (Skripsi) |
|---|---|
| Uncontrolled Keywords: | Talasemia, Analisis Efektivitas Biaya, Deferiprone, Deferasiroks. ---- Thalassemia, Cost Effectiveness Analysis, Deferiprone, Deferasirox |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine |
| Divisions: | Program Studi S1 Farmasi |
| Depositing User: | pustakawan - - |
| Date Deposited: | 14 Nov 2024 02:17 |
| Last Modified: | 14 Nov 2024 02:17 |
| URI: | http://repository.stfi.ac.id/id/eprint/1493 |
Actions (login required)
 |
View Item |
